AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 131 min read$A

Agilent to acquire Proscia for $240M in cash (A:NYSE)

Agilent Technologies (A) agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. The deal is expected to close in the second half of 2023.

Original reporting
seekingalpha.com
Published Oct 13, 2026, 12:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$A
Neutral
high confidence
Mentioned
$A
Relevance
9/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$ANeutralHigh
01

Why it matters

The acquisition expands Agilent's portfolio into AI‑driven pathology, aligning with its strategy to broaden life‑science offerings.

02

Market read

First‑report M&A news for a mid‑cap U.S. stock; likely moves the share price in pre‑market trading.

03

What to watch

Integration risk and potential regulatory review could delay benefits.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Agilent Technologies (A) is a leading provider of analytical instruments and life‑science solutions. Proscia is a digital pathology software company.

Company-level read

Ticker impact

$ANeutralHigh confidence
Context

Agilent announced a definitive agreement to acquire Proscia for $240M cash plus up to $30M milestones.

Expected impact

potential modest dip as the market prices the cash outflow, with upside if integration prospects are favored

Evidence & confidence

Cash deal of $240M is material for Agilent; first disclosure creates immediate pricing impact.

Market effects

Sector

Adds to consolidation trend in life‑science instrumentation and digital pathology.

Regional

U.S. market impact limited to Agilent; no broader regional effect.

Global

Minor global relevance, primarily affecting Agilent shareholders.

Counterpoint

What could challenge this read

The deal may overpay for Proscia, risking dilution of earnings per share.

Key entities

  • Company
    Agilent Technologies

    US‑listed provider of analytical instruments.

  • Company
    Proscia

    Digital pathology software firm.

Read at source← All news

StoryAgilent to acquire digital pathology firm Proscia for up to $270 million

Also covered by

3 outlets

Related articles

OCT 18
$AHighAI 9/10

Philadelphia's Proscia to Sell to Agilent for Up to $270M

Agilent Technologies (NYSE: A) agreed to acquire Proscia, a digital pathology software company, for up to $270M. The deal includes $240M upfront and $30M in performance-based payments. Proscia's software integrates AI tools and manages digital tissue images, serving over 4,000 labs and 16 top pharmaceutical firms. The acquisition aims to expand Agilent's presence in the $5B pathology market, combining its diagnostic instruments with Proscia's software.

mychesco.com2 min
OCT 18
$AHighAI 9/10

Philadelphia AI Cancer Diagnostics Firm Proscia Acquired for Up to $270M

Agilent Technologies (A) is acquiring Proscia, an AI cancer diagnostics firm, for up to $270M ($240M in cash, $30M in milestones). Proscia's software digitizes tissue samples for AI analysis, used by 4,000 labs and 16 top pharma companies. The deal expands Agilent's presence in digital pathology. Proscia will remain in Philadelphia, with the deal expected to close in early fiscal 2027.

philadelphia.today2 min
OCT 18
$AHighAI 9/10

Agilent Agrees to Buy Proscia for $240M

Agilent Technologies agreed to acquire Proscia for $240M in cash, with up to $30M more tied to performance milestones. Proscia's trailing revenue exceeded $18M. The deal will integrate Proscia's digital pathology software into Agilent's business, expected to close in early fiscal 2027.

quasa.io2 min
OCT 16
$BMBLHighAI 9/10

Deal Dispatch: Ithaca Holdings Buys Bumble for $1.3B, The Knot Acquires Zola, Character.ai Bankruptcy

Bumble (BMBL) agreed to a $1.3B all-cash acquisition by Ithaca Holdings, becoming privately held. IonQ will acquire Elisity in an all-stock deal up to $1.3B. Agilent (A) to buy Proscia for $240M. Workday (WDAY) acquiring C1.ai. Aurora Cannabis exploring alternatives to Curaleaf's bid. Character.ai filed for bankruptcy, Disney to pay $20M for IP. Getty Images plans Chapter 11, going private with Koch backing.

finance.yahoo.com3 min
OCT 14
$AHighAI 9/10

Agilent acquires Proscia in deal worth up to $270m

Agilent (A) will acquire Proscia for up to $270m, including $240m upfront and $30m for performance milestones. The deal aims to enhance Agilent's pathology portfolio with Proscia's digital pathology software, Concentriq Dx, which has FDA clearance. Proscia serves over 4,000 labs and 16 top pharma companies, according to Agilent. The acquisition is expected to close in Agilent's fiscal year 2027.

finance.yahoo.com2 min